Evolent Health Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results. Also, Truist Securities Upgraded the Stock From Hold to Buy and Raised Its Price Target From $28 to $33.
Evolent Health Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results. Also, Truist Securities Upgraded the Stock From Hold to Buy and Raised Its Price Target From $28 to $33.
evolent health股票在公司公布了超预期的Q2财报后交易上涨，此外，Truist证券将该股票评级从持有升级为买入，并将其目标价格从28美元上调至33美元。
Evolent Health Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results. Also, Truist Securities Upgraded the Stock From Hold to Buy and Raised Its Price Target From $28 to $33.
evolent health股票在公司公布了超预期的Q2财报后交易上涨，此外，Truist证券将该股票评级从持有升级为买入，并将其目标价格从28美元上调至33美元。